Korro Bio, Inc. short interest in 2024
In 2024, Korro Bio, Inc.'s disclosed short interest ran from 0.29% of shares outstanding on 12 Jan 2024 to 6.98% on 31 Dec 2024, a change of +6.69 percentage points. The year's high was 6.98% on 31 Dec 2024 and its low 0.29% on 12 Jan 2024, averaging 2.34% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.02 days on 31 Jan 2024. Full history: Korro Bio, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 0.29% (12 Jan 2024)
- End of year
- 6.98% (31 Dec 2024)
- Change
- +6.69 pp
- High
- 6.98% (31 Dec 2024)
- Low
- 0.29% (12 Jan 2024)
- Average
- 2.34%
- Highest days to cover
- 10.02 (31 Jan 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 0.29% | 7.16 | |
| 31 Jan 2024 | 0.30% | 10.02 | |
| 15 Feb 2024 | 0.30% | 8.07 | |
| 29 Feb 2024 | 0.34% | 6.17 | |
| 15 Mar 2024 | 0.35% | 2.63 | |
| 28 Mar 2024 | 1.35% | 2.26 | 10-K filed, results (8-K) |
| 15 Apr 2024 | 1.68% | 3.78 | |
| 30 Apr 2024 | 1.55% | 3.58 | |
| 15 May 2024 | 1.88% | 5.15 | 10-Q filed, results (8-K) |
| 31 May 2024 | 1.85% | 3.04 | |
| 14 Jun 2024 | 1.96% | 3.43 | |
| 28 Jun 2024 | 2.88% | 1.01 | |
| 15 Jul 2024 | 3.41% | 4.08 | |
| 31 Jul 2024 | 3.50% | 5.54 | |
| 15 Aug 2024 | 3.17% | 3.78 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 3.09% | 4.67 | |
| 13 Sep 2024 | 2.72% | 4.55 | |
| 30 Sep 2024 | 2.40% | 3.03 | |
| 15 Oct 2024 | 2.95% | 4.18 | |
| 31 Oct 2024 | 2.82% | 1.00 | |
| 15 Nov 2024 | 2.61% | 1.68 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 3.20% | 3.64 | |
| 13 Dec 2024 | 4.65% | 2.66 | |
| 31 Dec 2024 | 6.98% | 7.15 |
See also: Korro Bio, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.